Parexel International, a Boston-based global biopharmaceutical services provider, has established an alliance with University Hospitals Bristol National Health Service (NHS) Foundation Trust (UH Bristol), one of the largest specialist teaching and research hospital trusts in the United Kingdom.
The UH Bristol agreement continues to expand Parexel’s alliance network, which complements its dedicated team of experts and hospital-based early phase units, providing clients with access to diverse patient populations worldwide in key therapeutic areas.
“UH Bristol is an ideal alliance for us because of its experience in conducting clinical research, access to substantial patient populations and work across multiple therapeutic areas,” said Sy Pretorius, M.D., M.S., M.B.A., corporate vice president and worldwide head of early phase for Parexel. “Our focus is to provide more efficient delivery of better, faster go/no-go decisions.”
Professor David Wynick, research director at UH Bristol, said, “We believe this alliance furthers our objectives to develop collaborative and consultative research partnerships and support research of national and international excellence and innovation.”
UH Bristol, the region’s largest provider of medical and dental teaching, is a leading research center and one of the largest acute NHS trusts in the country. It employs over 7,900 people and delivers over 100 different clinical services from a group of nine hospitals in the heart of the city.
Parexel assists clients with complex early-phase trial design and execution from first-in-human (FIH) through proof-of-concept. It has hospital-based units in the U.S., Europe and South Africa, as well as a network of alliance sites.